Loading
Cancer, Lipids, and Metabolism / Immune Cells in Cancer / Ferroptosis and Cancer Prognosis · Review
Frontiers in Pharmacology · September 9, 2026
Raises a question worth testing. It does not answer one.
This narrative review surveys mechanistic hypotheses and early clinical observations linking Chinese medicine-based interventions to multiple pathways implicated in TNBC (apoptosis, ferroptosis, immune regulation, EMT, metabolism), but reports that clinical evidence in TNBC is limited to small, heterogeneous trials and that ferroptosis evidence remains preclinical-only. The authors recommend CMBIs be regarded as investigational adjunctive approaches pending product characterization, clinical exposure assessment, multicenter trials, and safety monitoring.
Narrative review. Literature on Chinese medicine-based interventions (licensed products, standardized formulations, experimental mixtures, isolated constituents) assessed for relevance to TNBC and methodological robustness; evidence spans preclinical and clinical studies with heterogeneous designs and endpoints.. Intervention: Chinese medicine-based interventions (CMBIs), including licensed or commercial multi-component products, standardized trial formulations, experimental botanical mixtures, and isolated constituents, fractions, or derivatives.
Ferroptosis evidence currently limited to preclinical Shuganning injection studies showing iron-dependent lipid peroxidation and ferrostatin-1-sensitive cell death, without clinical validation in TNBC 2022 meta-analysis reported favorable pooled estimates for TNBC-specific clinical outcomes but documented substantial methodological weaknesses and intervention heterogeneity Preclinical findings suggest pathway-associated effects involving apoptosis, ferroptosis, immune regulation, epithelial-mesenchymal transition, metabolism, and chemotherapy response
Ferroptosis evidence entirely preclinical; clinical applicability and safety in TNBC patients unknown
Clinicians should not consider Chinese medicine-based interventions established therapies for TNBC at present. The review identifies ferroptosis as a preclinically promising mechanism but notes the absence of clinical validation; further rigorous multicenter trials, product characterization, and safety monitoring are prerequisites before integration into standard TNBC care.
A narrative review mapping mechanistic evidence and clinical findings across heterogeneous Chinese medicine interventions in TNBC, acknowledging limited and methodologically weak clinical data and preclinical-only evidence for most mechanisms.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should not consider Chinese medicine-based interventions established therapies for TNBC at present. The review identifies ferroptosis as a preclinically promising mechanism but notes the absence of clinical validation; further rigorous multicenter trials, product characterization, and safety monitoring are prerequisites before integration into standard TNBC care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous breast cancer subtype with early recurrence and limited therapeutic targets. The evidence reviewed here spans several non-equivalent intervention classes: licensed or commercial multi-component Chinese medicine products, standardized trial formulations, experimental botanical mixtures, and isolated constituents, fractions, or derivatives. We use the umbrella term Chinese medicine-based interventions (CMBIs) only for evidence mapping and do not assume pharmacological, manufacturing, or regulatory equivalence among these classes. Evidence was appraised on two independent dimensions: relevance to TNBC and study design/methodological robustness. TNBC-specific clinical evidence is limited to a small number of randomized and observational studies with dissimilar endpoints; a 2022 meta-analysis reported favorable pooled estimates but also substantial methodological weaknesses and intervention heterogeneity. Preclinical findings suggest pathway-associated effects involving apoptosis, ferroptosis, immune regulation, epithelial-mesenchymal transition, metabolism, and chemotherapy response. Ferroptosis evidence is currently limited to preclinical Shuganning injection studies showing iron-dependent lipid peroxidation and ferrostatin-1-sensitive cell death, without clinical validation in TNBC. Overall, CMBIs should be regarded as investigational adjunctive approaches rather than established TNBC-specific therapies. Priorities include product-level chemical characterization, clinically relevant exposure assessment, model-diverse causal validation, multicenter trials, and preparation-specific safety and interaction monitoring.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.